David I. Sandoval's most recent trade in MaxCyte Inc was a trade of 353 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on March 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | 18 Mar 2025 | 353 | 64,219 | - | 3.2 | 1,122 | Common Stock | |
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | 14 Mar 2025 | 92,500 | 92,500 | - | - | Employee Stock Option (right to buy) | ||
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | 14 Mar 2025 | 23,125 | 64,572 | - | 0 | Common Stock | ||
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | 13 Jan 2025 | 4,466 | 41,447 | - | 4.5 | 20,272 | Common Stock | |
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 15,625 | 15,625 | - | - | Employee Stock Option (right to buy) | |
| MaxCyte Inc | David I. Sandoval | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 3,913 | 45,913 | - | 0 | Common Stock |